S*BIO regains rights from Onyx for JAK2 inhibitor program; Almirall to market co-brand of Nycomed's roflumilast in Spain
Privately-held Singapore-headquartered biotech firm S*BIO Pte has announced the restructuring of its collaboration and option agreement with US drug developer Onyx Pharmaceuticals (Nasdaq: ONXX), which was entered into in January 2009.
As a result, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx. Following a successful and productive partnership with Onyx, S*BIO says it will now be in a position to drive the development of its lead JAK2 program independently. S*BIO licensed the two products to Onyx in a deal that was worth a potential $550 million to the Singapore company, $25 million of which was paid upfront (The Pharma Letter January 12, 2009).
SB1518 promising in Phase II trials for MF
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze